Alice Shaw, Novartis' director of translational oncology

No­var­tis jumps in­to the KRAS race with a pos­i­tive ear­ly snap­shot — and a full slate of tri­als planned for am­bi­tious bid to un­seat Am­gen

NEW OR­LEANS — Am­gen may have won the race to first ap­proval among the KRAS G12C ri­vals, but that hasn’t de­terred No­var­tis from un­veil­ing an all-hands clin­i­cal cam­paign to get a best-of-class ri­val on­to the mar­ket.

No­var­tis tipped its hand at AACR22, high­light­ing ear­ly da­ta on JDQ443 that demon­strat­ed a con­firmed ORR of 57% — 4 of 7 pa­tients — at the high, 200 mg dose for non-small cell lung can­cer. That’s a sol­id de­but for monother­a­py re­sults, but the in­ves­ti­ga­tors on the project are look­ing to do much bet­ter with a line­up of com­bi­na­tion tri­als adding in a SHP2, in dose es­ca­la­tion since last June, along with their PD-1 in­hibitor tislelizum­ab and a triplet us­ing all 3.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.